TABLE 3.

Differential Improvements Over Time in Death-Censored Graft Survival and Patient Survival Across Various Subgroups of Pediatric (<18 years old) Kidney Transplant Recipients Between 1987 and 2012 (n = 17 446)

DCGS
	aHR (95% CI)	P
All patients	0.95 (0.94–0.96)	<.001
Recipient age
0–2 years	0.94 (0.92–0.96)	<.001
3–5 years	0.93 (0.91–0.95)	<.001
6–12 years	0.94 (0.93–0.95)	<.001
13–17 years	0.96 (0.95–0.96)	<.001
Recipient gender
Female	0.96 (0.95–0.97)	<.001
Male	0.94 (0.93–0.95)	<.001
Dialysis history
Preemptive	0.94 (0.92–0.95)	<.001
Pretransplant dialysis	0.95 (0.95–0.96)	<.001
Etiology of renal disease
FSGS	0.97 (0.95–0.98)	<.001
Other glomerular	0.95 (0.94–0.96)	<.001
CAKUT	0.94 (0.93–0.95)	<.001
Other/missing	0.95 (0.94–0.96)	<.001
Patient Survival
	aHR (95% CI)	P
All patients	0.95 (0.94–0.97)	<.001
Peak PRA
0%–20%	0.96 (0.95–0.97)	<.001
21%–80%	0.96 (0.93–0.98)	.002
81%–100%	0.90 (0.86–0.94)	<.001

CAKUT, congenital anomalies of the kidney and urinary tract; IQR, interquartile range.